The focus of this conference is to encourage new interdisciplinary approaches based on phages and plasmids that could be used to fight Antimicrobial Resistance (AMR).
The conference was co-organised by EVOPROG and INTEGRATE AMR. EVOPROG is an EU FET-Proactive consortium devoted to developing new technology to engineer molecules based on bacteriophages (phages), continuous cultures and evolution. EVOPROG exemplifies the usefulness of novel technologies and approaches to engineer phages, which could transform phage therapy as we know it today.
The conference facilitated discussions between specialists who have expertise in phages, virology, directed evolution, microbiology & microbial diversity and encourage collaborations to tackle AMR.
Our goal was to provide an innovative interface for directed evolutionary technologies and antimicrobial resistance, to foster learning, inspiration and wonder – and provoke conversations that matter.
In the age of genome sequencing and engineering, new emerging technologies can be used to design novel antimicrobial strategies:
1) Enhance existing antibiotics.
2) Alternative antimicrobials such as molecules derived from phages.
3) Synthetic phages or phage-like particles as antimicrobials.
|Ian Molineux, University of Texas at Austin||Martha Clokie, University of Leicester
David Harper, Evolution Biotechnologies
Andrzej Gorski, Polish Academy of Sciences
Mark van Raaij, Madrid CNB
Prof. Alfonso Jaramillo, Professor of Synthetic Biology
Coordinator of the EVOPROG consortium
Organised and funded by:
INTEGRATE AMR, 'Integrating expertise across disciplines to tackle antimicrobial resistance'
Venue: Royal Shakespeare Company. The Other Place, RSC, Stratford-upon-Avon
Dates: 15 & 16 Sep 2016
Start: 13:00 15 Sep (Lunch)